Changchun High-Tech Industry (000661.SZ): The application for clinical trials registration of injection drug GenSci136 produced domestically has been accepted.

17:43 02/04/2026

Changchun High-tech (000661.SZ) announced that its holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the "Notice of Acceptance" issued by the National Medical Products Administration for the clinical trial application for the domestic production of GenSci136 for injection. GenSci136 for injection is a type 1 biological product independently developed by Jinsai Pharmaceutical, intended for the treatment of ocular myasthenia gravis (oMG).

Changchun High-Tech Industry (000661.SZ) issued an announcement that its controlling subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received a "Notice of Acceptance" issued by the National Medical Products Administration for the domestic production drug registration clinical trial application of injection GenSci136. Injection GenSci136 is a Class 1 biological product developed independently by Jinsai Pharmaceutical, intended for the treatment of ocular myasthenia gravis (oMG).

Energy crisis does not hinder the expansion ambition: Microsoft Corporation (MSFT.US) increases investment in Japan by $10 billion, joining forces with SoftBank and Sakura to build AI cloud infrastructure.

BOCOM INTL: Maintain a buy rating on DATANG RENEW (01798) with a target price lowered to HK$1.81.

A-share midday review | Suppressed by three factors, the Shanghai Composite Index fell nearly 1% in half a day and lost the 3900 point mark! Technology sector leading the counterattack against the market.

BOCOM INTL: Maintain a buy rating on DATANG RENEW (01798) with a target price lowered to HK$1.81.